<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595449</url>
  </required_header>
  <id_info>
    <org_study_id>17-011142</org_study_id>
    <nct_id>NCT03595449</nct_id>
  </id_info>
  <brief_title>Lidocaine Jelly for Pain Control During Mohs Surgery</brief_title>
  <official_title>Patient Satisfaction in Mohs Micrographic Surgery With Supplemental Lidocaine Jelly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Does the use of lidocaine jelly during Mohs surgery on the nose decrease the total amount of&#xD;
      lidocaine used during surgery.&#xD;
&#xD;
      Does patient satisfaction improve when lidocaine jelly is used during Mohs surgery of the&#xD;
      nose?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Supplementing lidocaine/epinephrine injections with intralesional lidocaine jelly&#xD;
      will decrease the overall quantity of lidocaine/epinephrine injectable used, and will&#xD;
      decrease patients' self-reported pain/anxiety associated with needle sticks.&#xD;
&#xD;
      Objectives: To assess how using lidocaine jelly in Mohs surgery impacts 1) the overall&#xD;
      quantity of lidocaine/epinephrine injectable needed to maintain anesthesia, and 2) patients'&#xD;
      pain/anxiety associated with anesthesia injections.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Mohs micrographic surgery is a procedure that removes cancerous lesions of the skin in a&#xD;
      step-wise fashion. Patients are injected with local analgesia for tumor extirpation. The&#xD;
      tumor is removed and the tissue is sent for histopathology while the patient waits. Tissue&#xD;
      processing time can take up to 2 hours during which the effects of the local analgesia have&#xD;
      waned. Once the tissue has been process and examined, patients are brought back to the&#xD;
      surgical suite and either have another section of tissue removed (if the margins were&#xD;
      positive) or have the wound reconstructed (if the margins were negative). Lidocaine&#xD;
      Hydrochloride (Xylocaine) injection with Epinephrine is the traditionally method used to&#xD;
      maintain local anesthesia throughout the procedure. The FDA has declared a shortage of this&#xD;
      injectable Lidocaine/Epinephrine, stressing the need for a substitute drug. Additionally,&#xD;
      multiple needle sticks can be uncomfortable and anxiety provoking for patients. Needle sticks&#xD;
      on hypersensitive areas such as the nose can be particularly painful. Previous research has&#xD;
      demonstrated that a different form of anesthetic, a topical lidocaine jelly, is efficient in&#xD;
      prolonging anesthesia in Mohs surgery (Robins, 1991). No study has published the impact of&#xD;
      supplemental lidocaine jelly use on the overall quantity of injection needed, nor on patient&#xD;
      pain/anxiety associated with needle sticks.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      We will conduct a prospective, randomized trial of 250 patients receiving Mohs micrographic&#xD;
      surgery to lesions on the nose. Annually Mohs micrographic surgery is performed on&#xD;
      approximately 900 patients with 30% of these procedures being performed on lesions on the&#xD;
      nose. Patients receiving Mohs treatment for lesions on the nose will be randomly assigned to&#xD;
      one of two groups: (1) those whose wounds will be dressed with lidocaine jelly (treatment&#xD;
      group), and (2) those whose wounds will be dressed with surgical lubricant (control/placebo&#xD;
      group).&#xD;
&#xD;
      All patients will receive a pre-treatment baseline pain/anxiety survey followed by an initial&#xD;
      lidocaine injection. The amount of lidocaine/epinephrine injection each patient receives&#xD;
      throughout remaining stages of surgery will be recorded, as per the current workflow. All&#xD;
      patients will complete a second pain/anxiety survey immediately after numbing but prior to&#xD;
      the first stage of surgery.&#xD;
&#xD;
      After the first stage of surgery, either lidocaine jelly or surgical lubricant will be&#xD;
      applied to the wound followed by a pressure bandage as per standard practice. Dressing are&#xD;
      removed immediately prior to the next stage of surgery. After each subsequent stage of&#xD;
      surgery, an identical wound dressing will be placed on the operative site.&#xD;
&#xD;
      Immediately prior to each subsequent stage of surgery, we will assess patients' pain&#xD;
      sensation, and additional lidocaine/epinephrine will be injected if needed. After the&#xD;
      surgical site is re-anesthetized, vital signs will be recorded and the Pain/Anxiety survey&#xD;
      administered immediately prior to the first incision of that stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Patient Perception of Pain Score</measure>
    <time_frame>baseline to stage 1 of Mohs surgery, approximately one hour</time_frame>
    <description>The mean change of total pain score of patient perception of pain. As measured by the question &quot;Rate the pain of your nose from 0 to 10. 0 being no pain, 10 being the worst pain of your life.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Total Amount of Intervention (Lidocaine or Surgilube) Used</measure>
    <time_frame>Through completion of Mohs surgery, approximately one day</time_frame>
    <description>The mean total amount of intervention used as measured by milligrams (mg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Pain</condition>
  <condition>Satisfaction, Consumer</condition>
  <arm_group>
    <arm_group_label>Lidocaine jelly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the group that will have lidocaine jelly applied during Mohs surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgilube</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This is the group that will have surgilube (placebo) applied during Mohs surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine jelly</intervention_name>
    <description>lidocaine 2% jelly applied during Mohs surgery</description>
    <arm_group_label>Lidocaine jelly</arm_group_label>
    <other_name>lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surgilube</intervention_name>
    <description>surgilube (placebo) applied during Mohs surgery</description>
    <arm_group_label>Surgilube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients having Mohs surgery on the nose who are able to consent to the study &gt;18 years old&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        unable to consent for themselves known allergy to lidocaine Mohs surgery in locations other&#xD;
        than the nose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shari A Ochoa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <results_first_submitted>May 28, 2021</results_first_submitted>
  <results_first_submitted_qc>May 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2021</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Shari Ochoa MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03595449/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine Jelly</title>
          <description>This group had lidocaine jelly applied during Mohs surgery&#xD;
Lidocaine jelly: lidocaine 2% jelly applied during Mohs surgery</description>
        </group>
        <group group_id="P2">
          <title>Surgilube</title>
          <description>This group had surgilube (placebo) applied during Mohs surgery&#xD;
Surgilube: surgilube (placebo) applied during Mohs surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine Jelly</title>
          <description>This group had lidocaine jelly applied during Mohs surgery&#xD;
Lidocaine jelly: lidocaine 2% jelly applied during Mohs surgery</description>
        </group>
        <group group_id="B2">
          <title>Surgilube</title>
          <description>This group had surgilube (placebo) applied during Mohs surgery&#xD;
Surgilube: surgilube (placebo) applied during Mohs surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="233"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.2" spread="10.46"/>
                    <measurement group_id="B2" value="71.7" spread="11.38"/>
                    <measurement group_id="B3" value="72.0" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Patient Perception of Pain Score</title>
        <description>The mean change of total pain score of patient perception of pain. As measured by the question &quot;Rate the pain of your nose from 0 to 10. 0 being no pain, 10 being the worst pain of your life.&quot;</description>
        <time_frame>baseline to stage 1 of Mohs surgery, approximately one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Jelly</title>
            <description>This group had lidocaine jelly applied during Mohs surgery&#xD;
Lidocaine jelly: lidocaine 2% jelly applied during Mohs surgery</description>
          </group>
          <group group_id="O2">
            <title>Surgilube</title>
            <description>This group had surgilube (placebo) applied during Mohs surgery&#xD;
Surgilube: surgilube (placebo) applied during Mohs surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Patient Perception of Pain Score</title>
          <description>The mean change of total pain score of patient perception of pain. As measured by the question &quot;Rate the pain of your nose from 0 to 10. 0 being no pain, 10 being the worst pain of your life.&quot;</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.2" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Amount of Intervention (Lidocaine or Surgilube) Used</title>
        <description>The mean total amount of intervention used as measured by milligrams (mg)</description>
        <time_frame>Through completion of Mohs surgery, approximately one day</time_frame>
        <population>Data was not collected or analyzed for four subjects in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Jelly</title>
            <description>This group had lidocaine jelly applied during Mohs surgery&#xD;
Lidocaine jelly: lidocaine 2% jelly applied during Mohs surgery</description>
          </group>
          <group group_id="O2">
            <title>Surgilube</title>
            <description>This group had surgilube (placebo) applied during Mohs surgery&#xD;
Surgilube: surgilube (placebo) applied during Mohs surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Amount of Intervention (Lidocaine or Surgilube) Used</title>
          <description>The mean total amount of intervention used as measured by milligrams (mg)</description>
          <population>Data was not collected or analyzed for four subjects in each arm</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="29.0"/>
                    <measurement group_id="O2" value="24.4" spread="18.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline to end of study, approximately one day for each subject</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine Jelly</title>
          <description>This group had lidocaine jelly applied during Mohs surgery&#xD;
Lidocaine jelly: lidocaine 2% jelly applied during Mohs surgery</description>
        </group>
        <group group_id="E2">
          <title>Surgilube</title>
          <description>This group had surgilube (placebo) applied during Mohs surgery&#xD;
Surgilube: surgilube (placebo) applied during Mohs surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shari A. Ochoa, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>480-301-6479</phone>
      <email>Ochoa.Shari@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

